Scarica l'app Stockscreener
1.06
1.92%
0.02
Dopo l'orario di chiusura:
1.06
Precedente Chiudi:
$1.04
Aprire:
$1.05
Volume 24 ore:
285.95K
Relative Volume:
0.98
Capitalizzazione di mercato:
$23.93M
Reddito:
-
Utile/perdita netta:
$-13.76M
Rapporto P/E:
-1.1398
EPS:
-0.93
Flusso di cassa netto:
-
1 W Prestazione:
-6.19%
1M Prestazione:
-14.52%
6M Prestazione:
+46.98%
1 anno Prestazione:
-1.85%
Intervallo 1D:
$1.01
$1.08
Intervallo di 1 settimana:
$1.01
$1.14
Portata 52W:
$0.512
$2.33
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Nome
Neurosense Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.06 | 23.93M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie
NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World
NeuroSense regains Nasdaq compliance with equity boost - Investing.com
NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria
NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com
Neurosense Therapeutics Ltd (NRSN-Q) QuotePress Release - The Globe and Mail
Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) & Avidity Biosciences (NASDAQ:RNA) - Defense World
NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC - TipRanks
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - Nasdaq
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd - Defense World
NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position - TipRanks
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results - citybiz
NeuroSense's ALS Drug Shows Breakthrough Results: 58% Better Survival Rate in Phase 2b Trial - StockTitan
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) - Aktiellt
NeuroSense Therapeutics Regains Nasdaq Compliance - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Hold” Rating from Maxim Group - Defense World
Maxim cuts NeuroSense shares rating to hold on capital concerns By Investing.com - Investing.com South Africa
Maxim cuts NeuroSense shares rating to hold on capital concerns - Investing.com
Comparing Emmaus Life Sciences (OTCMKTS:EMMA) & NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense aligns with FDA on Phase 3 ALS drug study By Investing.com - Investing.com Australia
NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment - TipRanks
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Desig - GuruFocus.com
NeuroSense aligns with FDA on Phase 3 ALS drug study - Investing.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - Marketscreener.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC (PR Newswire) - Aktiellt
Dewpoint Therapeutics and Mitsubishi Tanabe partner on ALS therapy - European Biotechnology News
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - The Malaysian Reserve
NeuroSense Announces Completion of PARADIGM Study Highlighting P - GuruFocus.com
NeuroSense Therapeutics Ltd. Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS - Marketscreener.com
NeuroSense’s PrimeC Shows Promise in ALS Treatment - TipRanks
NeuroSense Therapeutics Ltd. announced that it expects to receive $5 million in funding - Marketscreener.com
NeuroSense secures $5 million in private placement funds By Investing.com - Investing.com Nigeria
NeuroSense Therapeutics Announces Securities Purchase Agreement - TipRanks
NeuroSense Therapeutics Announces $5 Million Private Placement - citybiz
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price - Lelezard
NeuroSense secures $5 million in private placement funds - Investing.com India
NeuroSense Secures $5M Private Placement at 25% Premium, CEO Joins Investment - StockTitan
Exosome Diagnostics & Therapeutics Market Assessment - GlobeNewswire
NeuroSense Therapeutics Plans to File for Early Commercializatio - GuruFocus.com
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Tr - GuruFocus.com
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstr - GuruFocus.com
NeuroSense Advances Plans for Early Commercialization of Groundb - GuruFocus.com
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS, MND - Marketscreener.com
NeuroSense Therapeutics Ltd. announced that it expects to receive $30 million in funding - Marketscreener.com
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - PR Newswire
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS i - GuruFocus.com
NeuroSense Therapeutics Secures Continued Nasdaq Listing - TipRanks
Neurosense Therapeutics Ltd Azioni (NRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):